[
    [
        {
            "time": "",
            "original_text": "医药生物公司上半年业绩分化 关注政策影响小或优势独特的细分龙头 盈利能力下降",
            "features": {
                "keywords": [
                    "医药生物",
                    "业绩分化",
                    "政策影响",
                    "细分龙头",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物公司上半年业绩分化 关注政策影响小或优势独特的细分龙头 盈利能力下降",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]